Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Oncology Institute (DFPH) Common Equity (2020 - 2025)

Historic Common Equity for Oncology Institute (DFPH) over the last 6 years, with Q3 2025 value amounting to -$12.3 million.

  • Oncology Institute's Common Equity fell 17927.92% to -$12.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$12.3 million, marking a year-over-year decrease of 17927.92%. This contributed to the annual value of $3.6 million for FY2024, which is 9370.63% down from last year.
  • Per Oncology Institute's latest filing, its Common Equity stood at -$12.3 million for Q3 2025, which was down 17927.92% from -$9.0 million recorded in Q2 2025.
  • In the past 5 years, Oncology Institute's Common Equity registered a high of $132.0 million during Q1 2022, and its lowest value of -$12.3 million during Q3 2025.
  • For the 5-year period, Oncology Institute's Common Equity averaged around $60.1 million, with its median value being $50.4 million (2021).
  • Per our database at Business Quant, Oncology Institute's Common Equity soared by 38621.83% in 2021 and then crashed by 17927.92% in 2025.
  • Quarter analysis of 5 years shows Oncology Institute's Common Equity stood at $104.2 million in 2021, then increased by 18.26% to $123.2 million in 2022, then crashed by 53.7% to $57.0 million in 2023, then tumbled by 93.71% to $3.6 million in 2024, then plummeted by 441.99% to -$12.3 million in 2025.
  • Its Common Equity was -$12.3 million in Q3 2025, compared to -$9.0 million in Q2 2025 and $5.1 million in Q1 2025.